At the end of the FIT studies, the between-treatment group differences were 3.2 mm in the Three-Year Study and 1.3 mm in the Four-Year Study.The therapeutic equivalence of once-weekly Fosamax 70 mg (n=519) and Fosamax 10 mg daily (n=370) was demonstrated in a one-year, double-blind, multicenter study of postmenopausal women with osteoporosis.

However, there was an apparent increased incidence of upper gastrointestinal adverse reactions in patients taking Fosamax 40 mg/day (17.7% Fosamax vs. 10.2% placebo). High doses of cortisone medications are used to treat giant cell arteritis.You are encouraged to report negative side effects of prescription drugs to the FDA.

However, there was an increased occurrence of vomiting in osteogenesis imperfecta patients treated with Fosamax compared to placebo.

No significant effect was seen for total body BMD.Histomorphometric studies of transiliac biopsies in 92 subjects showed normal bone architecture. In these studies the overall safety profiles of Fosamax 5 mg/day and placebo were similar. Treatment of menopausal symptoms varies, and should be discussed with your physician.Paget's disease is a chronic bone disorder due to irregular breakdown and formation of bone tissue. At the cellular level, alendronate shows preferential localization to sites of bone resorption, specifically under osteoclasts. The impact of variables such as time between cessation of bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of administration (intravenous versus oral) on the risk has not been studied.The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. In contrast, Fosamax 5 mg/day prevented bone loss in the majority of patients and induced significant increases in mean bone mass at each of these sites (see Bone histology was normal in the 28 patients biopsied at the end of three years who received Fosamax at doses of up to 10 mg/day.The therapeutic equivalence of once weekly Fosamax 35 mg (n=362) and Fosamax 5 mg daily (n=361) was demonstrated in a one-year, double-blind, multicenter study of postmenopausal women without osteoporosis.

Do not lie down.You may get allergic reactions, such as hives or swelling of your face, lips, tongue, or throat.Tell your doctor if you have any side effect that bothers you or that does not go away.These are not all the possible side effects of Fosamax.

Patients presenting with an atypical fracture should also be assessed for symptoms and signs of fracture in the contralateral limb. At one year, the mean increases relative to placebo in BMD in men receiving Fosamax 70 mg once weekly were significant at the following sites: lumbar spine, 2.8%; femoral neck, 1.9%; trochanter, 2.0%; and total body, 1.2%. If you would like more information, talk with your doctor.

The optimal duration of use has not been determined.

The intent of the study was to recruit women with osteoporosis, defined as a baseline femoral neck BMD at least two standard deviations below the mean for young adult women.

At the cellular level, alendronate shows preferential localization to sites of bone resorption, specifically under osteoclasts. Adverse reactions from these studies considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 1% of patients treated with either Fosamax or placebo are presented in The safety of Fosamax 70 mg once weekly for the treatment of postmenopausal osteoporosis was assessed in a one-year, double-blind, multicenter study comparing Fosamax 70 mg once weekly and Fosamax 10 mg daily. In the long-term studies, reductions from baseline in serum calcium (approximately 2%) and phosphate (approximately 4 to 6%) were evident the first month after the initiation of Fosamax 10 mg. No further decreases in serum calcium were observed for the five-year duration of treatment; however, serum phosphate returned toward prestudy levels during years three through five.

Unless one experiences a fracture, a person may have osteoporosis for decades without knowing it. These fractures can occur anywhere in the femoral shaft from just below the lesser trochanter to above the supracondylar flare and are transverse or short oblique in orientation without evidence of comminution. Patients in the study had either a BMD T-score less than or equal to -2 at the femoral neck and less than or equal to -1 at the lumbar spine, or a BMD T-score less than or equal to -2 at the lumbar spine and less than or equal to -1 at the femoral neck, or a baseline osteoporotic fracture and a BMD T-score less than or equal to -1 at the femoral neck.

Study 1 and Study 2 were identically designed, three-year, placebo-controlled, double-blind, multicenter studies (United States and Multinational n=994); Study 3 was the three-year vertebral fracture cohort of the Fracture Intervention Trial [FIT] (n=2027) and Study 4 was the four-year clinical fracture cohort of FIT (n=4432). The bisphosphonate class includes The recommended dose for treatment of osteoporosis is 5-10 mg daily or 35-70 mg weekly.

Mechanism of Action .